Alorica and Talkdesk Announce Strategic Partnership to Deploy Next Generation of Customer Experience
17.3.2021 16:30:00 EET | Business Wire | Press release
Alorica, a global leader in customer experience (CX) solutions, and Talkdesk®, Inc., the leading cloud contact center for innovative enterprises, today announced a strategic partnership to deliver turnkey CX solutions. The partnership brings together Talkdesk’s cloud-based contact center platform with Alorica’s award-winning operational execution and best-in-class workforce, providing clients with a complete solution to build customer satisfaction, loyalty and long-term value through a scalable, cost-efficient and secure implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005568/en/
“Many businesses are facing the challenge of needing to invest and scale more robust customer service and experience requirements amidst uncertain economic outlooks,” said Greg Haller, chief operating officer, Alorica. “With a deep understanding of the customer and how digital platforms are redefining our industry, Alorica is investing in the right technology and partners that will help our clients navigate their CX transformation successfully. The combined, complementary capabilities of Alorica and Talkdesk give clients a differentiated pathway to cost-effectively elevate the customer experience. Ultimately, this leads to brand loyalty, revenue growth and operational efficiencies.”
Modern consumer expectations have advanced beyond voice-only support to include web, messaging, mobile applications and social platforms as part of the customer journey. In response, service models must deliver fast and easy customer engagement, across all channels, in a way that is both personalized and contextual at every customer touchpoint. However, companies are challenged to activate new technology, high-quality talent and world-class operational models at an accelerated pace while simultaneously reducing risk and improving efficiency.
“Talkdesk is passionate about driving the contact center industry forward with innovative solutions, providing companies with the solutions and flexible consumption-based pricing options they need to set themselves apart from their competition,” said Tiago Paiva, chief executive officer, Talkdesk. “The customer-first philosophy shared by Alorica and Talkdesk helps enterprises around the world build brand trust and loyalty by delivering exceptional customer interactions.”
Alorica and Talkdesk are joining forces to achieve these goals, enabling a more comprehensive understanding of client needs and the ability to quickly provide tailored offerings. Through their combined capabilities, clients will benefit from an integrated operating model for hiring, training, analytics, knowledge management, quality assurance, call routing and automation. Talkdesk’s native cloud platform complements Alorica’s embedded systems and empowers a skilled workforce, giving clients an industry-leading and strategic executional partner to efficiently establish and scale the latest CX solutions through a single interface at a fraction of the cost of building standalone operations.
By leveraging Talkdesk CX Cloud™, Alorica further enhances its enterprise performance at scale on behalf of clients around the world, resulting in increased productivity, customer satisfaction and cost savings. Through this one-of-a-kind partnership, Alorica and Talkdesk are setting a new benchmark for the contact center solutions market with scalability, security and reliability. This is backed not only by Talkdesk’s 100% uptime Service Level Agreement, but also implemented through one of the largest customer experience providers in the world—Alorica.
Additional Resources:
- Alorica positioned highest as a Leader in Gartner’s 2021 Magic Quadrant for Customer Service BPO for its ability to execute
- See how Alorica’s cloud-based, work-at-home delivery model, Alorica Anywhere, enables the ability to rapidly deploy a secure solution onsite or at home, anywhere in the world
- See Talkdesk as a Leader by Gartner in the 2020 Magic Quadrant for Contact Center as a Service (CCaaS) and other recent awards and recognition
- Hear directly from customers why they selected Talkdesk CX Cloud and the difference it has made in their contact centers
- Talkdesk recently announced $143 million in Series C funding, increasing the company’s valuation to more than $3 billion
Tweet this : Ready for the next generation of #CX? @OfficialAlorica and @Talkdesk are excited to announce a new strategic partnership as an integrated solution to help brands deploy global omnichannel experiences tailored to their business
Social Networks:
- Web: www.alorica.com
- Insights: https://www.alorica.com/insights/
- Twitter: https://twitter.com/OfficialAlorica
- LinkedIn: https://www.linkedin.com/company/alorica
- Facebook: https://www.facebook.com/AloricaFanPage
- Instagram: https://www.instagram.com/officialalorica/
- Web: https://www.talkdesk.com
- Blog: https://www.talkdesk.com/blog/
- Twitter: https://twitter.com/Talkdesk
- LinkedIn: https://www.linkedin.com/company/talkdesk/
- Facebook: https://www.facebook.com/Talkdesk/
- Instagram: https://www.instagram.com/Talkdesk/
About Alorica
We are made up of 100,000 passionate problem solvers who make lives better through positive customer interactions—at every touchpoint—across voice, chat and social. Leveraging innovative technologies—including intelligent automation and a comprehensive analytics suite—we support the world’s most respected brands with the best talent and resources necessary to create insanely great experiences. Alorica provides a host of world-class services—from customer care to financial solutions and digital services—to clients across industries of all kinds, many of whom are on the Fortune 500. Alorica contact centers and operation hubs span the globe with locations in 14 countries. To learn more, visit www.Alorica.com.
About Talkdesk
Talkdesk® is the cloud contact center for innovative enterprises. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and YMCA rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005568/en/
Contact information
Alorica
Sunny Yu
sunny.yu@alorica.com
(714) 469-8385
Talkdesk
Christie Blake
christie.blake@talkdesk.com
(781) 405-3616
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
